Ibvilda 50mg Tablet contains Vildagliptin, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By selectively inhibiting the DPP-4 enzyme, Vildagliptin enhances the levels of incretin hormones, which increase insulin secretion from pancreatic beta cells and decrease glucagon release from alpha cells in a glucose-dependent manner. This dual action helps improve glycemic control without causing significant hypoglycemia. Ibvilda is typically prescribed as monotherapy in patients inadequately controlled by diet and exercise or as an adjunct to other antidiabetic agents such as metformin or insulin. The recommended dose is 50 mg twice daily, with dosage adjustments based on renal function and therapeutic response. Clinical trials have demonstrated that Vildagliptin effectively reduces HbA1c levels with a favorable safety profile, exhibiting minimal risk of weight gain and hypoglycemia. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances, though these are generally mild and transient. Ibvilda should be used cautiously in patients with hepatic impairment and is contraindicated in individuals with type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose and renal function is advised during therapy to optimize treatment outcomes.